FindTrial
Sign In

Comparison of effect of Marma Therapy And Mukta Vati In in Stage I Hypertension

A Multi-Centre Study: Comparison of Marma Therapy and Mukta Vati in The Treatment of Stage I Hypertension

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025898
Enrollment
120
Registered
2020-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Mukta Vati In The Treatment of Stage I Hypertension: Mukta vati (300 mg) 1 tablet twice a day for 1 month (Oral route) Intervention2: Marma Therapy In The Treatment of Stage I Hypertens

Sponsors

Patanjali Research Institute Haridwar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects will be enrolled with stage I HTN. Subjects who are drug-naïve will be enrolled for the study with normal LV function.

Exclusion criteria

Exclusion criteria: LVEF CKD, Serum creatinine > 1.7

Design outcomes

Primary

MeasureTime frame
Ambulatory BP (24 hr BP) Biochemical markers: Lipid profile Fasting glucose HbA1C Serum K+ Proteinuria LFT KFT Hs-CRP Serum cortisol Serum Insulin level Timepoint: every week 0-3months—

Secondary

MeasureTime frame
BPTimepoint: 0-3 months—

Countries

India

Contacts

Public ContactProf R B Sati

Main Campus, Uttarakhand Ayurved University

drsatirb@gmail.com8077747461

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026